Loading...
Market
What will be the market share of Nemluvio® in the US Prurigo Nodularis treatment market by August 13, 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Market research reports from credible sources like IMS Health or IQVIA
Story
Galderma Gains FDA Approval for Nemluvio® to Treat Prurigo Nodularis
Aug 13, 2024, 05:09 AM
Galderma, a Swiss pharmaceutical company, has received approval from the U.S. Food and Drug Administration (FDA) for its drug Nemluvio® (nemolizumab). This medication is intended for adult patients suffering from Prurigo Nodularis, a chronic skin condition characterized by itchy nodules. The FDA approval marks a significant advancement for Galderma in the U.S. market, providing a new treatment option for patients with this challenging dermatological condition.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 20% • 25%
20% - 40% • 25%
40% - 60% • 25%
More than 60% • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 25% • 25%
25%-50% • 25%
51%-75% • 25%
More than 75% • 25%
0-25% • 25%
25-50% • 25%
50-75% • 25%
Above 75% • 25%